← OncoDesk·MedDesk·web edition — reference only, not medical advice
all sections · full handbook

2Lung

Snapshot. SCLC (small-cell lung cancer, ~15%) vs NSCLC (non-small-cell lung cancer, ~85%: adenocarcinoma, squamous, large cell). In non-squamous NSCLC, molecular profiling + PD-L1 are mandatory before first-line treatment — a driver mutation gets a matched TKI (tyrosine kinase inhibitor), not immunotherapy first. ⚠ Giving IO before the NGS result is back is harmful — no benefit in a driver-mutant tumour, and it raises the toxicity of the TKI that should have come first (esp. pneumonitis risk with osimertinib after PD-1/PD-L1 exposure).
Workup
Contrast CT chest/abdomen → PET/CT (nodal + distant staging) → brain MRI (lung is brain-tropic — don't skip) · bronchoscopic / CT-guided biopsy ± EBUS-TBNA for mediastinal nodes (one act, two jobs — biopsies AND stages the mediastinum) — first and biggest split: SCLC vs NSCLC · NSCLC → reflex NGS (EGFR, ALK, ROS1, BRAF, KRAS-G12C, MET, RET, NTRK, HER2) + PD-L1 (TPS), mandatory before 1st-line⚠ never start immunotherapy before the results are back.
Treatment by setting
SettingTreatment
Early / resectable NSCLC
NSCLC · no mets · operable
Surgery — lobectomy + mediastinal nodal sampling the anchor of curative treatment
Perioperative chemo-immunotherapy around surgery neoadjuvant-only nivolumab (CheckMate-816) (5-yr update confirms an OS benefit, ~30% reduction in risk of death, ASCO 2025) · full perioperative (neo + adjuvant) pembrolizumab (KEYNOTE-671) or durvalumab (AEGEAN)
EGFR-mutant → adjuvant osimertinib ×3 yr (ADAURA)
ALK-positive → adjuvant alectinib (ALINA) 76% reduction in recurrence/death vs chemo · both targeted options REPLACE chemo-IO when the driver is present
Medically inoperable → SABR stereotactic ablative radiotherapy
Stage III, unresectable
NSCLC · N2/N3 or unresectable · no mets
Concurrent chemoradiotherapy → consolidation durvalumab (PACIFIC)
EGFR-mutant → consolidation osimertinib instead (LAURA) PFS 39.1 vs 5.6 months
⚠ Durvalumab CONCURRENTLY with chemoRT does not help (PACIFIC-2) it stays sequential / consolidative — after chemoRT finishes
Metastatic NSCLC — DRIVER-POSITIVE
NGS: actionable driver found
Matched TKI — the driver picks the drug ⚠ NGS must be back before first-line treatment. Most of these are absent in any given patient — scan for the one you have:
EGFR → osimertinib (FLAURA) (or amivantamab + lazertinib (MARIPOSA), 1st-line-approved 2024) · ALK → alectinib (ALEX) / lorlatinib (CROWN) · ROS1 → repotrectinib / crizotinib · BRAF V600E → dabrafenib + trametinib · MET exon-14 skipping → capmatinib / tepotinib · RET fusion → selpercatinib / pralsetinib · NTRK fusion → larotrectinib / entrectinib · HER2-mutant → trastuzumab deruxtecan (or zongertinib, an oral HER2 TKI, approved 2025)
⚠ KRAS-G12C is NOT a first-line driver treat as driver-negative below (PD-L1-stratified chemo ± IO); sotorasib / adagrasib are reserved for 2nd-line+
⚠ NOT immunotherapy first for any driver above
Metastatic NSCLC — DRIVER-NEGATIVE
NGS: no actionable driver (includes KRAS-G12C) + PD-L1 TPS
PD-L1 ≥50% → pembrolizumab alone (KEYNOTE-024)
PD-L1 <50% → chemo + pembrolizumab (KEYNOTE-189) non-squamous · (KEYNOTE-407) squamous
Chemo backbone non-squamous → platinum + pemetrexed · squamous → platinum + gemcitabine / paclitaxel
Palliative RT for symptomatic sites · brain mets → SRS / WBRT
SCLC — LIMITED stage
confined to one hemithorax, fits one RT field
Platinum + etoposide + concurrent thoracic RT → consolidation durvalumab (ADRIATIC) 27% reduction in risk of death; median OS 55.9 vs 33.4 months — the first phase 3 survival gain in limited-stage SCLC in decades
Consider PCI or MRI surveillance prophylactic cranial irradiation
SCLC — EXTENSIVE stage
distant metastases
Platinum + etoposide + a PD-L1 inhibitor atezolizumab (IMpower133) or durvalumab (CASPIAN)
2nd line → TARLATAMAB is PREFERRED over chemotherapy (DeLLphi-304) a DLL3 bispecific T-cell engager · phase 3 randomised it against chemo — and lurbinectedin, topotecan and amrubicin were the COMPARATOR arm: median OS 13.6 vs 8.3 mo, HR 0.60, 12-mo OS 53% vs 37% · ⚠ it was also BETTER TOLERATED (fewer grade ≥3 treatment-related AEs, fewer interruptions/reductions) — so the usual reason for holding it back does not hold · earlier accelerated approval on (DeLLphi-301)
⚠ Do NOT save tarlatamab for last giving lurbinectedin / topotecan first and holding tarlatamab in reserve gives the patient the arm that LOST the trial, at the point they are fittest to tolerate the better drug. The legitimate reasons to use chemo instead are logistics or access, not efficacy: tarlatamab needs step-up dosing with CRS/ICANS monitoring capacity, and it must be available/funded
Chemotherapy options if tarlatamab is unavailable → lurbinectedin · topotecan · amrubicin and if PLATINUM-SENSITIVE relapse (beyond ~6 months) → platinum re-challenge is also legitimate — do not skip past it
Watch
On immunotherapy, new dyspnoea = pneumonitis vs progression vs infection — image first. Osimertinib → ILD, QTc prolongation, cardiomyopathy. Amivantamab → infusion reactions, VTE, paronychia/skin toxicity. Tarlatamab → cytokine release syndrome + ICANS (neurotoxicity) — first doses need inpatient monitoring. Immune-related adverse events across organs on any checkpoint inhibitor.
← BreastBladder / Urothelial →